NEW YORK (
CHANGE IN RATINGS
downgraded at Goldman from Buy to Neutral. Valuation call, though estimates were boosted because of lower production costs. $128 price target.
upgraded at Needham from Hold to Buy. $31 price target. Company is positioned well to benefit from a new up-cycle.
upgraded at Goldman from Neutral to Buy. Company trades at an attractive valuation and can deliver 18% production growth in 2011.
upgraded at Credit Suisse to Outperform from Neutral on valuation and a strong cash position. $56 price target. 2009 and 2010 EPS estimates set at $4.08 and $4.36, respectively.
downgraded at Credit Suisse to Underperform from Neutral as competition in the Mexican housing market is picking up.
downgraded at BofA/Merrill to Neutral from Buy on worries that organic growth in 2H10 could be challenging. Price target reduced to $15 from $18.
upgraded at Citi to Buy from Hold on valuation and bullish on OKS's NGL assets. Maintain $65 price target.
downgraded at Thomas Weisel to Market Weight from Overweight on SSD inventory overhang at its largest customer EMC. Price target plunged to $8 from $31. 2010 EPS estimate lowered to $0.30 from $2.05.
upgraded at Morgan Stanley from Underweight to Equal-weight. Stock is pricing in lower shoe sales and markdown trends are improving. New $27 price target.
STOCK COMMENTS / EPS CHANGES
price target increased at BofA/Merrill to $29 from $27 on sustainable growth. 2011 EPS raised to 72 cents, 2012 cut to 94 cents. Neutral rating.
estimates, target boosted at UBS. ADSK estimates were increased through 2012. Company is seeing accelerating demand momentum. Buy rating and new $36 price target.
estimates, target increased at UBS. Shares of AMED now seen reaching $70. Estimates also raised, because of Medicare rate increases. Buy rating.
Blue Coat Systems
target, estimates boosted at BofA/Merrill. BCSI price target raised by $2 to $32 on better revenues and margins. Estimates improved through 2012. Maintain Buy rating.
Blue Coat Systems
numbers increased at FBR. Shares of BCSI now seen reaching $28. Estimates also boosted, because of early success of the company's restructuring plan. Market Perform rating.
Barnes & Noble
numbers reduced at Goldman. BKS estimates were cut through 2012. Company is boosting its digital investments. Sell rating and new $16 price target.
Church & Dwight
numbers boosted at Goldman. CHD estimates were increased through 2012. Company is seeing higher gross margins. Neutral rating and new $72 price target.
numbers reduced at Goldman. CNL estimates were lowered through 2012. JPM agreement will hurt earnings. Sell rating and new $26 price target.
target raised at UBS. GNW target was upped to $18.50. Company is improving its ROE, with the outlook for mortgage insurance improving. Buy rating.
estimates raised at Morgan Stanley through 2011. Company is seeing higher EBIT margins, as housing recovers. Overweight rating and $35 price target.
numbers boosted at Goldman. HD estimates were increased through 2012. Company is realizing higher EBIT margins. Buy rating and new $35 price target.
estimates raised at Goldman through 2011. Company is seeing a better environment for bad-debt expenses. Neutral rating and $9 price target.
target, estimates cut at BofA/Merrill. IPGP price target trimmed by a dollar to $20. 4Q09 results top line beat, but margins lag noted Bank of America/Merrill Lynch. 2010 EPS estimate lowered to 46 cents. Maintain Buy rating.
numbers cut at Goldman. Shares of KMB now seen reaching $63. Estimates also lowered, because of expected commodity inflation. Neutral rating.
estimates upped at Morgan Stanley. LOW estimates were increased through 2012. Company should return to positive comp sales this year. Overweight rating and $27 price target.
estimates lowered at Morgan Stanley. MDT estimates were reduced through 2012. Organic growth is slowing. Equal-weight rating.
estimates boosted at UBS through 2011. Company is gaining market share in ICD's and seeing lower expenses. Buy rating and $53 price target.
estimates lowered at Morgan Stanley through 2011. Company is seeing multiple headwinds. Overweight rating and $75 price target.
price target trimmed at BofA/Merrill by a dollar to $28. Valuation attractive, but obscured by nuclear expansion. Maintain Buy rating.
price target raised at BofA/Merrill to $4.20 from $3.50 on improved liquidity and better than expected 4Q09 results. Estimates raised through 2012. Reiterate Underperform rating.
estimates, target upped at Goldman. Shares of ODP now seen reaching $7. Estimates also raised, as the company is realizing higher gross margins. Neutral rating.
Procter & Gamble
numbers raised at Goldman. Shares of PG now seen reaching $70. Estimates also increased, given higher expected profit in liquid laundry detergent. Neutral rating.
target, estimates slashed at Credit Suisse. QCOM price target sunk to $40 from $45 on chipset margin pressure. 2010 and 2011 EPS estimates lowered to $2.17 and $2.30, respectively. Maintain Neutral rating.
estimates reduced at Goldman through 2011. Company is seeing lower comp sales. Sell rating and $61 price target.
numbers reduced at Goldman. Shares of THC now seen reaching $8. Estimates also cut, because of planned technology investments. Buy rating.
price target raised at Credit Suisse to $37 from $34 after strong 4Q09 results. Maintain Neutral rating.
numbers lowered at Goldman through 2011. Company is seeing weak pricing in vinyls. Sell rating and new $22 price target.
price target raised at BofA/Merrill to $36 from $34 as stock and volumes are intertwined. 2010 EPS lowered to $2.16, 2011 raised to $2.65, 2012 introduced at $3.03. Maintain Buy rating.
estimates cut at UBS through 2010. Company is facing unfavorable currency rates. Neutral rating and $28 price target.
This article was written by a staff member of TheStreet.com.